+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Construction of live vaccines using genetically engineered poxviruses biological activity of vaccinia virus recombinants expressing the hepatitis b virus surface antigen and the herpes simplex virus glyco protein d



Construction of live vaccines using genetically engineered poxviruses biological activity of vaccinia virus recombinants expressing the hepatitis b virus surface antigen and the herpes simplex virus glyco protein d



Proceedings of the National Academy of Sciences of the United States of America 81(1): 193-197



Potential live vaccines using recombinant vaccinia viruses have been constructed for both hepatitis B and herpes simplex. These recombinant vaccinia viruses express cloned genes of the hepatitis B virus surface antigen (HBsAg) or the glycoprotein D from herpes simplex virus (HSV-gD). The HBsAg synthesized in vitro under the regulation of vaccinia virus is secreted from infected African green monkey kidney CV-1 cells as a particle of .apprx. 22 nm diameter with a density of 1.2 g/ml as determined on CsCl gradients. Inoculation of rabbits with the recombinant vaccinia virus that expresses the HBsAg elicits the production of high-titered antibodies. Synthesis of the HSV-gD was detected in tissue culture by radioimmunoassay on unfixed cells, suggesting that the HSV-gD synthesized by the recombinant vaccinia virus is membrane associated. Inoculation of rabbits with the recombinant vaccinia virus expressing HSV-gD resulted in the production of antibodies that reacted with authentic HSV-gD as detected by radioimmunoassay. The antiserum was shown by plaque-reduction assay to neutralize the infectivity of herpes simplex virus. Immunization of mice with the vaccinia recombinant expressing HSV-gD gave complete protection on subsequent challenge with lethal doses of live herpes simplex virus.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 005040263

Download citation: RISBibTeXText

PMID: 6320164


Related references

Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proceedings of the National Academy of Sciences of the United States of America 80(17): 5364-5368, 1983

Live vaccinia virus recombinants expressing herpes simplex virus genes. Reviews of Infectious Diseases 13(Suppl. 11): S898-S903, 1991

Construction and in vivo evaluation of two genetically engineered prototypes of live attenuated herpes simplex virus vaccines. Chanock, R M , Et Al (Ed ) Vaccines, 87 Modern Approaches to New Vaccines: Prevention Of Aids And Other Viral, Bacterial, And Parasitic Diseases; Conference, Cold Spring Harbor, New York, Usa, 1986 Xxiii+461p Cold Spring Harbor Laboratory: Cold Spring Harbor, New York, Usa Illus Paper 368-373, 1987

Construction of an infectious vaccinia virus recombinant expressing the hepatitis b virus surface antigen and epstein barr virus membrane antigen. Chinese Journal of Virology 4(1): 1-7, 1988

Vaccinia virus recombinants as potential herpes simplex virus vaccines. Advances in Experimental Medicine and Biology 327: 183-189, 1992

Double variolovaccine recombinants expression hepatitis b virus surface antigen and herpes simplex virus thymidine kinase. Doklady Akademii Nauk SSSR 289(6): 1493-1496, 1986

Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proceedings of the National Academy of Sciences of the United States of America 79(16): 4927-4931, 1982

Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. 1982. Biotechnology 24: 503-507, 1992

Evaluation of antiviral immunity using vaccinia virus recombinants expressing cloned genes for herpes simplex virus type 1 glycoproteins. Journal of General Virology 70: 1359-1370, 1989

Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D. Reviews of Infectious Diseases 13(Suppl. 11): S924-S934, 1991

Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D. Journal of Infectious Diseases 155(6): 1188-1197, 1987

Antigen-presenting capacity of epidermal cells infected with vaccinia virus recombinants containing the herpes simplex virus glycoprotein D, and protective immunity. Journal of General Virology 70: 2513-2520, 1989

Recombinant vaccinia virus expressing the herpes simplex virus type 1 glycoprotein C protects mice against herpes simplex virus challenge. Journal of General Virology 70: 2587-2594, 1989

Expression of human immunodeficiency virus type 1 gag gene using genetically engineered herpes simplex virus type 1 recombinants. Virus Genes 4(4): 325-337, 1990

Herpes simplex virus glyco proteins participation of individual herpes simplex virus type 1 glyco protein antigens in immuno cytolysis and their correlation with previously identified glyco poly peptides. Journal of Virology 32(3): 741-748, 1979